107841-22-5

Upstream product

• 21086-33-9 2-bromo-1-(4-methoxyphenyl)-1-propanone 
• 103-49-1 dibenzylamine 

Downstream Products

• 50802-67-0 2-amino-1-(4-methoxyphenyl)propan-1-ol 
• 63991-23-1 erythro 1-(p-methoxyphenyl)-2-amino-1-propanol hydrochloride 
• 92903-30-5 cis 2-(p-methoxyphenyl)-3-methylmorpholine hydrochloride 
• 92903-30-5 trans 2-(p-methoxyphenyl)-3-methylmorpholine hydrochloride 
• 63991-23-1 threo 1-(p-methoxyphenyl)-2-amino-1-propanol hydrochloride 
• 107841-27-0 2-Bromo-N-[2-hydroxy-2-(4-methoxy-phenyl)-1-methyl-ethyl]-acetamide 
• 107841-27-0 2-Bromo-N-[2-hydroxy-2-(4-methoxy-phenyl)-1-methyl-ethyl]-acetamide 
• 107841-28-1 cis 2-(p-methoxyphenyl)-3-methyl-5-morpholinone 
• 107841-28-1 trans 2-(p-methoxyphenyl)-3-methyl-5-morpholinone 

Relevant academic research and scientific papers

CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS

The present invention is directed to certain cinnoline compounds of formula (I) that are PDE10 inhibitors, pharmaceutical compositions containing such compounds and process for preparing such compounds. The invention is also directed to methods of treating diseases treatable by modulation of PDE10 enzyme, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS

The present invention is directed to cinnoline and quinazoline compounds of formula (I) that are PDE10 inhibitors, pharmaceutical compounds containing the same and processes for preparing the same. The invention is also directed to methods of treating diseases mediated by PDE10 enzyme such as obesity, non-insulin dependent diabetes, schizophrenia or bipolar disorder, obsessive-compulsive disorder, and the like.

SYNTHESIS OF RIGID DOPAMINE CONGENERS: CIS AND TRANS 2-(p-METHOXYPHENYL)-3-METHYLMORPHOLINE

A synthetic pathway is reported for the preparation of cis and trans forms of 2-(p-methoxyphenyl)-3-methyl-morpholine from the same key-compound, the p-methoxy- -(N,N'-dibenzylamino)-propiophenone, through stereospecific reduction processes.